Lym-X-Sorb® (Lymphatic Xenobiotic AbSorbability), winner of the 2004 Eurand Award, is a unique drug delivery system with controlled release. Lym-X-Sorb® was developed as an analogue to the basic products of fat digestion by David. W. Yesair, PhD., founder of BioMolecular Products, Inc. and is trademarked and proprietary to BioMolecular Products, Inc., holder of five US and 11 foreign patents. Dr. Yesair first described the physiologic arrangement between the principal products of fat digestion, lipids, specifically lysophosphatidylcholine (LPC), monoglyceride (MG) and fatty acid (FA). In the intestinal lumen, these lipids form a unique three-dimensional, non-liposomal monomeric unit that is absorbed in the jejunum. Once reconstituted into chylomicrons, these lipids are transported via the thoracic lymph and enter the systemic circulation thru venous blood at the juncture of the subclavian vein. When manufactured and formulated with a drug agent or nutraceutical, the Lym-X-Sorb® monomer shields the drug or neutriceutical from the hostile environs of the stomach and the upper intestine by enveloping it in the void created among the acyl-constituents of the lipid anchors. Directing this "lipid glove" from the intestinal lumen to the lymphatic system is the body's underlying mechanism for fat absorption. Lym-X-Sorb® is manufactured with Generally Regarded as Safe (GRAS) lipid materials in a range of molar ratios: 1:2:4 to 1:4:2 LPG:MG:FA respectively, and Lym-X-Sorb® can be lamellar, hexagonal, inverse hexagonal, or other.
- FDA's GRAS components and patent protected.
- Forms stable eutectic Lym-X-Sorb®/xenobiotic complexes.
- Organized Eutectic Structure: lamellar, hexagonal, inverse hexagonal in a range of molar ratios. Eutectic organization demonstrates a single melting point which is lower than the melting points of the individual components.
- Animal and Human Safety Studies—non-toxic.
- Stable in aqueous environments.
- Compatible with many biological surfaces.
- Commercial and economical production.
- Maximum oral drug absorption with slow and sustained delivery.
- Protects drugs in gastro-intestinal milieu.
- Nutritional: can be made into candy bars, cookies, powders.
- Dermatological: can be applied topically.
- Pharmaceutical: Delivery of drugs via the lymph to the systemic circulation at the junction of the left subclavian vein will enhance the delivery of drugs at greater concentrations and higher therapeutic effectiveness to the heart, lung and brain.
- Optimal range of molar ratios is 1:4:2 to 1:2:4, LPC:MG:FA.
- Molecular organization of LPC:MG:FA (1:4:2) as a monomeric structure binds one mole of drug.
- Adopts lamellar structural organization at approximately zero water content and with the addition of 0-8 or more moles of water, Lym-X-Sorb® adopts hexagonal, inverse hexagonal or other arrangement.
- Can be a liquid or solid at room temperature by varying the unsaturation of the fatty acids.
- Low surface tension (25 dynes/cm).
- Forms small particles in physiological (intestinal) [70nm to <10nm].
- Viscosity increases as the water content increases.
Bioavailability of Oral Lym-X-Sorb®:
- Readily absorbable delivery vehicle.
- Absorbed in the upper intestine.
- Enhanced absorption of drug, lipids, vitamins.
- Minimizes variation of bioavailability of drug.
- Stable in physiological concentrations of sodium bicarbonate and bile salt (sodium taurocholate) present in the intestines.
The molecular structure of Lym-X-Sorb® is a stable way to bring medicines into the system far more effectively than other conventional means. Briefly, an included drug or certain nutraceutical within the Lym-X-Sorb® eutectic complex can result in enhanced oral drug bioavailability in animals and humans, for example ca. 15% to 90%. Lym-X-Sorb® can deliver equivalent therapeutic value with much smaller quantities of a medicine, potentially reducing toxicity. Diverse drug structures have been shown to be compatible with Lym-X-Sorb®, both topically and orally.